Based on our current findings, we propose that obesity-induced systemic factors promote breast cancer progression and may increase resistance to aromatase inhibitor therapy by initiating crosstalk between nongenomic ERα activity and the IGF-1R, PI3K/Akt and MAPK signaling pathways. Here, IGF1R is linked to obesity due to melanocortin 4 receptor deficiency.